170 related articles for article (PubMed ID: 11888936)
21. A fluorescence-based sensor for calibrated measurement of protein kinase stability in live cells.
Paul JW; Muratcioğlu S; Kuriyan J
Protein Sci; 2024 Jun; 33(6):e5023. PubMed ID: 38801214
[TBL] [Abstract][Full Text] [Related]
22. Degradable Cross-Linked Nanoassemblies as Drug Carriers for Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-demethoxy-geldanamycin.
Ponta A; Akter S; Bae Y
Pharmaceuticals (Basel); 2011 Sep; 4(10):1281-1292. PubMed ID: 27721325
[TBL] [Abstract][Full Text] [Related]
23. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
Gu TL; Tothova Z; Scheijen B; Griffin JD; Gilliland DG; Sternberg DW
Blood; 2004 Jun; 103(12):4622-9. PubMed ID: 14962911
[TBL] [Abstract][Full Text] [Related]
24. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Morris SW; Kirstein MN; Valentine MB; Dittmer KG; Shapiro DN; Saltman DL; Look AT
Science; 1994 Mar; 263(5151):1281-4. PubMed ID: 8122112
[TBL] [Abstract][Full Text] [Related]
25. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Bonvini P; Dalla Rosa H; Vignes N; Rosolen A
Cancer Res; 2004 May; 64(9):3256-64. PubMed ID: 15126367
[TBL] [Abstract][Full Text] [Related]
26. Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?
Lovisa F; Garbin A; Crotti S; Di Battista P; Gallingani I; Damanti CC; Tosato A; Carraro E; Pillon M; Mafakheri E; Romanato F; Gaffo E; Biffi A; Bortoluzzi S; Agostini M; Mussolin L
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33562105
[TBL] [Abstract][Full Text] [Related]
27. NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.
Andraos E; Dignac J; Meggetto F
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33466277
[TBL] [Abstract][Full Text] [Related]
28. CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.
Kuravi S; Parrott E; Mudduluru G; Cheng J; Ganguly S; Saunthararajah Y; Jensen RA; Blagg BS; McGuirk JP; Balusu R
Blood Cancer J; 2019 Jan; 9(2):14. PubMed ID: 30696805
[No Abstract] [Full Text] [Related]
29. Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.
Cao Z; Gao Q; Fu M; Ni N; Pei Y; Ou WB
Oncol Lett; 2019 Feb; 17(2):2020-2030. PubMed ID: 30675269
[TBL] [Abstract][Full Text] [Related]
30. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.
Jiang L; Xie C; Lung HL; Lo KW; Law GL; Mak NK; Wong KL
Theranostics; 2018; 8(19):5307-5319. PubMed ID: 30555548
[TBL] [Abstract][Full Text] [Related]
31. [HSP90 inhibitor 17-AAG plays an important role in JAK3/STAT5 signaling pathways in HTLV-1 infection cell line HUT-102].
Yang QQ; Tan H; Fu ZP; Ma Q; Song JL
Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):710-715. PubMed ID: 28954352
[No Abstract] [Full Text] [Related]
32. ALK: a tyrosine kinase target for cancer therapy.
Holla VR; Elamin YY; Bailey AM; Johnson AM; Litzenburger BC; Khotskaya YB; Sanchez NS; Zeng J; Shufean MA; Shaw KR; Mendelsohn J; Mills GB; Meric-Bernstam F; Simon GR
Cold Spring Harb Mol Case Stud; 2017 Jan; 3(1):a001115. PubMed ID: 28050598
[TBL] [Abstract][Full Text] [Related]
33. Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study.
Kim P; Jia P; Zhao Z
Brief Bioinform; 2018 May; 19(3):450-460. PubMed ID: 28013235
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.
Buetti-Dinh A; O'Hare T; Friedman R
PLoS One; 2016; 11(9):e0163011. PubMed ID: 27669408
[TBL] [Abstract][Full Text] [Related]
35. The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.
Alshareef A; Zhang HF; Huang YH; Wu C; Zhang JD; Wang P; El-Sehemy A; Fares M; Lai R
Sci Rep; 2016 Sep; 6():33710. PubMed ID: 27641368
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities.
Tabbò F; Pizzi M; Kyriakides PW; Ruggeri B; Inghirami G
Oncotarget; 2016 May; 7(18):25064-86. PubMed ID: 26943776
[TBL] [Abstract][Full Text] [Related]
37. Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.
Peron M; Lovisa F; Poli E; Basso G; Bonvini P
PLoS One; 2015; 10(7):e0132330. PubMed ID: 26147305
[TBL] [Abstract][Full Text] [Related]
38. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
Cameron L; Solomon B
Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
[TBL] [Abstract][Full Text] [Related]
39. The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins.
Hakuno F; Fukushima T; Yoneyama Y; Kamei H; Ozoe A; Yoshihara H; Yamanaka D; Shibano T; Sone-Yonezawa M; Yu BC; Chida K; Takahashi S
Front Endocrinol (Lausanne); 2015; 6():73. PubMed ID: 26074875
[TBL] [Abstract][Full Text] [Related]
40. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.
Vijayvergia N; Mehra R
Cancer Chemother Pharmacol; 2014 Sep; 74(3):437-46. PubMed ID: 25135623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
